Published in Mol Cell Endocrinol on February 04, 2010
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab (2012) 1.39
Hyperparathyroid genes: sequences reveal answers and questions. Endocr Pract (2011) 0.95
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery (2010) 0.89
RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 0.86
Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas. PLoS One (2010) 0.85
Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies. Diagn Pathol (2014) 0.83
Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model. Carcinogenesis (2013) 0.81
Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis. Cancer Sci (2015) 0.81
Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules. Curr Genomics (2014) 0.80
The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer. Gland Surg (2013) 0.78
Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma. Oncotarget (2016) 0.78
Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision. Thyroid Res (2010) 0.78
The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS One (2015) 0.77
BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg (2016) 0.77
Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients. PLoS One (2015) 0.76
Follicular Variant of Papillary Thyroid Carcinoma: Hybrid or Mixture? Thyroid (2016) 0.75
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma. Sci Rep (2017) 0.75
MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer. Int J Mol Sci (2017) 0.75
RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study. Oncol Lett (2015) 0.75
Expression of Notch 1 receptor associated with tumor aggressiveness in papillary thyroid carcinoma. Onco Targets Ther (2016) 0.75
Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer. Curr Genomics (2014) 0.75
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell Int (2017) 0.75
Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma. Clin Exp Med (2016) 0.75
Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma. World J Surg (2016) 0.75
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2008) 5.29
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res (2005) 1.77
[Diagnosis and treatment of thyroid cancer - Polish guidelines]. Endokrynol Pol (2010) 1.56
Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol (2005) 1.46
Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase and participates in degradation of IL-1beta mRNA. FEBS J (2009) 1.44
Welcome to thyroid research. Thyroid Res (2008) 1.40
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol (2004) 1.31
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer (2005) 1.15
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
Genome-wide association study on differentiated thyroid cancer. J Clin Endocrinol Metab (2013) 1.03
Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab (2007) 1.02
Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol (2004) 1.02
Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med (2007) 0.98
Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett (2004) 0.98
Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. Thyroid (2005) 0.98
A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer (2007) 0.95
Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr Rev (2007) 0.95
Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol (2009) 0.93
13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res (2009) 0.92
Association between age at diagnosis of Graves' disease and variants in genes involved in immune response. PLoS One (2013) 0.90
BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. Front Biosci (Elite Ed) (2011) 0.88
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer (2014) 0.87
Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal. BMC Genomics (2009) 0.87
Gene expression profile of human thyroid cancer in relation to its mutational status. J Mol Endocrinol (2011) 0.86
Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease: the impact of DRB1*07. Thyroid (2006) 0.85
NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma. Folia Histochem Cytobiol (2009) 0.85
Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab (2006) 0.84
Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt) (2006) 0.84
Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. Int Arch Allergy Immunol (2009) 0.84
Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res (2010) 0.83
Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers - the role of Ct serum level. Thyroid Res (2013) 0.82
Diagnostics and Treatment of Thyroid Carcinoma. Endokrynol Pol (2016) 0.82
Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Med Genomics (2013) 0.81
Role of nuclear medicine imaging in differential diagnosis of accessory spleens in patients after splenectomy. Pol J Radiol (2012) 0.81
[Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi]. Endokrynol Pol (2006) 0.81
Novel therapies for thyroid cancer. Expert Opin Pharmacother (2014) 0.80
[Completion total thyroidectomy in children with differentiated thyroid cancer]. Endokrynol Pol (2006) 0.80
Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proc Natl Acad Sci U S A (2010) 0.80
[Gene expression profile of medullary thyroid carcinoma--preliminary results]. Endokrynol Pol (2006) 0.80
Analysis of nm23-H1 protein immunoreactivity in follicular thyroid tumors. Pol J Pathol (2004) 0.80
Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia. J Appl Genet (2011) 0.79
TNF-alpha expression in gastric mucosa of individuals infected with different virulent Helicobacter pylori strains. Med Sci Monit (2009) 0.79
Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin Pharmacother (2015) 0.79
Germinal mutations of RET, SDHB, SDHD, and VHL genes in patients with apparently sporadic pheochromocytomas and paragangliomas. Endokrynol Pol (2010) 0.79
The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study. Endokrynol Pol (2015) 0.78
Long-term survival and nearly asymptomatic course of carcinoid tumour with multiple metastases (treated by surgery, chemotherapy, (90)Y-DOTATATE, and LAR octreotide analogue): a case report. Endokrynol Pol (2009) 0.78
[Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)]. Endokrynol Pol (2008) 0.78
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells. Mol Cancer (2014) 0.78
[Relapse of differentiated thyroid carcinoma in low-risk patients]. Endokrynol Pol (2006) 0.78
Analysis of P161NK4A protein expression in follicular thyroid tumors. Pol J Pathol (2004) 0.77
[Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)]. Endokrynol Pol (2008) 0.77
[Hypoparathyroidism after surgery on thyroid cancer: is there a delayed chance for recovery after a prolonged period of substitutive therapy?]. Endokrynol Pol (2006) 0.77
[Gene expression analysis by DNA microarray in papillary thyroid cancer]. Endokrynol Pol (2006) 0.77
[Histopathological diagnosis of thyroid cancer in a multicenter trial]. Endokrynol Pol (2006) 0.76
[Management of Graves' orbitopathy. Comments on the EUGOGO consensus statement]. Endokrynol Pol (2009) 0.76
Application of Bayesian networks for inferring cause-effect relations from gene expression profiles of cancer versus normal cells. Math Biosci (2007) 0.76
Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients. Endokrynol Pol (2016) 0.76
Unsupervised analysis of follicular thyroid tumours transcriptome by oligonucleotide microarray gene expression profiling. Endokrynol Pol (2013) 0.76
Permanent effects of postnatal administration of beta-adrenergic ligands on the volume of sexually dimorphic nucleus of the preoptic area (SDN-POA) in rats. Neuro Endocrinol Lett (2006) 0.76
Clinical utility gene card for: multiple endocrine neoplasia type 2. Eur J Hum Genet (2011) 0.76
Expression profiles of signal transduction genes in ex vivo drug-resistant pediatric acute lymphoblastic leukemia. Anticancer Res (2012) 0.76
Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors. Pol J Pathol (2004) 0.75
[131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences]. Endokrynol Pol (2008) 0.75
[Adenoid cystic carcinoma--a case report]. Otolaryngol Pol (2002) 0.75
A study of thyroglobulin concentration in the thyroid and serum of patients with different thyroid disorders. Arch Immunol Ther Exp (Warsz) (2002) 0.75
[Indications for surgery of thyroid cancer based on bioptate molecular examination]. Endokrynol Pol (2006) 0.75
Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors. Pol J Pathol (2005) 0.75
Polish Thyroid Cancer Guidelines. Endokrynol Pol (2011) 0.75
[Application of DNA microcarriers for evaluation of mice splenocytes genes expression after immunization with pertussis vaccines and challenged with different B. pertussis strains]. Med Dosw Mikrobiol (2007) 0.75
[The importance of bisoprolol in prevention of heart left ventricular hypertrophy in patients with long term L-thyroxin suppressive therapy, after the operation of differentiated thyroid carcinoma]. Endokrynol Pol (2007) 0.75
Age at diagnosis and gender modify the risk of 9q22 and 14q13 polymorphisms for papillary thyroid carcinoma. Endokrynol Pol (2017) 0.75
Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Sci Rep (2017) 0.75
Has differentiated thyroid cancer (DTC) staging changed with in the last ten years in the Silesia region of Poland? Endokrynol Pol (2010) 0.75
Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results. Nucl Med Rev Cent East Eur (2002) 0.75
[Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences]. Endokrynol Pol (2006) 0.75
Loss of heterozygosity in 73 human thyroid tumors. Neuro Endocrinol Lett (2005) 0.75
Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy. Folia Histochem Cytobiol (2017) 0.75
The role of positron emission tomography in mediastinal staging of patients with non-small cell lung cancer. J Pak Med Assoc (2015) 0.75
[Anaplastic thyroid carcinoma in a 14-year-old boy]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw (2005) 0.75
[Medullary thyroid carcinoma: from molecular studies to clinical decision]. Endokrynol Pol (2005) 0.75
Diagnostics and treatment of differentiated thyroid carcinoma in children - Guidelines of Polish National Societies. Endokrynol Pol (2016) 0.75